Pancreatic Cancer UK Grand Challenge: Developments and challenges for effective CAR T cell therapy for pancreatic ductal adenocarcinoma.

[1]  Yongping Song,et al.  Engineering switchable and programmable universal CARs for CAR T therapy , 2019, Journal of Hematology & Oncology.

[2]  I. Magalhaes,et al.  Metabolic regulation of CAR T cell function by the hypoxic microenvironment in solid tumors. , 2019, Immunotherapy.

[3]  F. McCormick.  Progress in targeting RAS with small molecule drugs. , 2019, The Biochemical journal.

[4]  S. Varambally,et al.  Inhibition of Hedgehog signaling reprograms the dysfunctional immune microenvironment in breast cancer , 2018, Oncoimmunology.

[5]  B. Larimer.  Reporter Genes for PET Imaging of CAR T Cells Offers Insight into Adoptive Cell Transfer , 2018, The Journal of Nuclear Medicine.

[6]  Axel Schambach,et al.  Engineering CAR-T Cells for Improved Function Against Solid Tumors , 2018, Front. Immunol..

[7]  Wenchuan Wu,et al.  CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer , 2018, Journal of Translational Medicine.

[8]  C. Mackall,et al.  Tumor Antigen Escape from CAR T-cell Therapy. , 2018, Cancer discovery.

[9]  J. Kench,et al.  Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma , 2018, Gut.

[10]  S. Patel,et al.  Hypoxia-Driven Immunosuppressive Metabolites in the Tumor Microenvironment: New Approaches for Combinational Immunotherapy , 2018, Front. Immunol..

[11]  A. LeBeau,et al.  The role of CD133 in cancer: a concise review , 2018, Clinical and Translational Medicine.

[12]  C. June,et al.  Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  Hans Anton Schlößer,et al.  Cytokine release syndrome , 2018, Journal of Immunotherapy for Cancer.

[14]  K. Curran,et al.  Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  Alexander H. E. Morrison,et al.  Immunotherapy and Prevention of Pancreatic Cancer. , 2018, Trends in cancer.

[16]  H. D. Liggitt,et al.  Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates. , 2018, Cancer discovery.

[17]  C. Neuzillet,et al.  Immune therapies in pancreatic ductal adenocarcinoma: Where are we now? , 2018, World journal of gastroenterology.

[18]  C. Doglioni,et al.  Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells , 2018, Nature Medicine.

[19]  M. Sadelain,et al.  CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade , 2018, Nature Medicine.

[20]  M. Spitzer,et al.  Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System , 2018, Cell reports.

[21]  Zhiqiang Wu,et al.  CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial , 2018, Oncoimmunology.

[22]  C. June,et al.  Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. , 2018, JCI insight.

[23]  J. Maher,et al.  Clinically compliant spatial and temporal imaging of chimeric antigen receptor T-cells , 2018, Nature Communications.

[24]  Ken Garber,et al.  Driving T-cell immunotherapy to solid tumors , 2018, Nature Biotechnology.

[25]  B. Sacchetti,et al.  CAR-T cells: the long and winding road to solid tumors , 2018, Cell Death & Disease.

[26]  Max A. Horlbeck,et al.  Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins , 2018, eLife.

[27]  W. Han,et al.  Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy , 2018, Biomarker Research.

[28]  Y. Zu,et al.  Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  H. Abken,et al.  CAR T Cells Releasing IL-18 Convert to T-Bethigh FoxO1low Effectors that Exhibit Augmented Activity against Advanced Solid Tumors. , 2017, Cell reports.

[30]  Stephen J. Schuster,et al.  Chimeric Antigen Receptor T Cells in Refractory B‐Cell Lymphomas , 2017, The New England journal of medicine.

[31]  R. Levy,et al.  Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.

[32]  Xianjun Yu,et al.  Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going , 2017, Experimental & Molecular Medicine.

[33]  M. Ruella,et al.  Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf , 2017, BioDrugs.

[34]  J. Machiels,et al.  Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types , 2017, BMJ Open.

[35]  R. Korn,et al.  Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours , 2017, British Journal of Cancer.

[36]  Zhengfei Lu,et al.  Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor–Modified T Cells Engineered to Secrete Checkpoint Inhibitors , 2017, Clinical Cancer Research.

[37]  Wei-Chun Chang,et al.  Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[38]  D. Spriggs,et al.  Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment , 2017, Scientific Reports.

[39]  J. Mayerle,et al.  Roles of autophagy and metabolism in pancreatic cancer cell adaptation to 1 environmental challenges , 2017 .

[40]  J. Rathmell,et al.  Similarities and Distinctions of Cancer and Immune Metabolism in Inflammation and Tumors. , 2017, Cell metabolism.

[41]  A. Moody,et al.  Abstract CT109: HITM-SIR: Phase Ib trial of CAR-T hepatic artery infusions and selective internal radiation therapy for liver metastases , 2017 .

[42]  S. Halford,et al.  The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity , 2017, Cancer Immunology, Immunotherapy.

[43]  M. Falasca,et al.  Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies , 2017, International journal of molecular sciences.

[44]  O. Stasikowska-Kanicka,et al.  Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis , 2017, Disease markers.

[45]  C. June,et al.  Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells. , 2017, Cancer discovery.

[46]  D. Teachey,et al.  The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL). , 2017 .

[47]  Daniel M. Corey,et al.  PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumor immunity , 2017, Nature.

[48]  J. Friedberg,et al.  Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  I. Diaconu,et al.  Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[50]  I. Pastan,et al.  Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma , 2017, Oncotarget.

[51]  Guoyao Wu,et al.  Amino-acid transporters in T-cell activation and differentiation , 2017, Cell Death & Disease.

[52]  I. Riaz,et al.  Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review. , 2017, Immunotherapy.

[53]  Alan Maréchal,et al.  An oxygen sensitive self-decision making engineered CAR T-cell , 2017, Scientific Reports.

[54]  S. Violette,et al.  Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[55]  H. Heslop,et al.  Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[56]  Yunfei Guo,et al.  Masked Chimeric Antigen Receptor for Tumor-Specific Activation. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[57]  J. Gartner,et al.  T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. , 2016, The New England journal of medicine.

[58]  S. Grupp,et al.  Interleukin 6 Is Not Made By Chimeric Antigen Receptor T Cells and Does Not Impact Their Function , 2016 .

[59]  J. Friedberg,et al.  Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1 , 2016 .

[60]  T. Shichinohe,et al.  Clinical impact of chemotherapy to improve tumor microenvironment of pancreatic cancer , 2016, World journal of gastrointestinal oncology.

[61]  M. Geyer,et al.  Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells. , 2016, Cytotherapy.

[62]  Kole T. Roybal,et al.  Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors , 2016, Cell.

[63]  P. Lin,et al.  Expansion and functions of myeloid-derived suppressor cells in the tumor microenvironment. , 2016, Cancer letters.

[64]  S. Heimfeld,et al.  Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells , 2016, Science Translational Medicine.

[65]  He Huang,et al.  Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy , 2016, Journal of Hematology & Oncology.

[66]  A. Hemminki,et al.  Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[67]  Yuli Lin,et al.  FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3-CCL2 Signaling. , 2016, Cancer research.

[68]  J. Kochenderfer,et al.  Toxicities of chimeric antigen receptor T cells: recognition and management. , 2016, Blood.

[69]  H. Kiyoi,et al.  A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration , 2016, Cancer Immunology Research.

[70]  Alexandria P. Cogdill,et al.  Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. , 2016, Immunity.

[71]  Chan Hyuk Kim,et al.  Design of Switchable Chimeric Antigen Receptor T Cells Targeting Breast Cancer. , 2016, Angewandte Chemie.

[72]  G. Wertheim,et al.  Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. , 2016, Cancer discovery.

[73]  M. Brown,et al.  GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[74]  D. Mankoff,et al.  Concurrent SPECT/PET-CT imaging as a method for tracking adoptively transferred T-cells in vivo , 2016, Journal of Immunotherapy for Cancer.

[75]  D. Kuang,et al.  PD-1hi Identifies a Novel Regulatory B-cell Population in Human Hepatoma That Promotes Disease Progression. , 2016, Cancer discovery.

[76]  G. Freeman,et al.  Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model , 2016, Oncotarget.

[77]  K. Curran,et al.  Toxicity and management in CAR T-cell therapy , 2016, Molecular therapy oncolytics.

[78]  C. June,et al.  A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. , 2016, Cancer research.

[79]  W. Han,et al.  Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer , 2016, Science China Life Sciences.

[80]  D. Bartlett,et al.  Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer , 2016, Oncotarget.

[81]  D. Gabrilovich,et al.  The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. , 2016, Trends in immunology.

[82]  D. Bar-Sagi,et al.  IL35-Producing B Cells Promote the Development of Pancreatic Neoplasia. , 2016, Cancer discovery.

[83]  Kole T. Roybal,et al.  Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits , 2016, Cell.

[84]  R. Holcombe,et al.  Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer , 2016, Clinical Cancer Research.

[85]  J. Yang,et al.  Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors , 2015, Cancer Immunology Research.

[86]  R. Salgia,et al.  Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  S. Ugel,et al.  Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. , 2015, The Journal of clinical investigation.

[88]  T. Whiteside.  The role of regulatory T cells in cancer immunology , 2015, ImmunoTargets and therapy.

[89]  E. Puré,et al.  Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells. , 2015, Cancer research.

[90]  Michel Sadelain,et al.  The pharmacology of second-generation chimeric antigen receptors , 2015, Nature Reviews Drug Discovery.

[91]  R. Blasberg,et al.  Comparative Analysis of T Cell Imaging with Human Nuclear Reporter Genes , 2015, The Journal of Nuclear Medicine.

[92]  D. Linehan,et al.  CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. , 2015, Cancer research.

[93]  A. Hemminki,et al.  Favorable Alteration of Tumor Microenvironment by Immunomodulatory Cytokines for Efficient T-Cell Therapy in Solid Tumors , 2015, PloS one.

[94]  Chung-Pin Li,et al.  Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial , 2015, Oncotarget.

[95]  D. Torigian,et al.  Safety and antitumor activity of chimeric antigen receptor modified T cells in patients with chemotherapy refractory metastatic pancreatic cancer. , 2015 .

[96]  Michael A. Choti,et al.  Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets , 2015, Nature Communications.

[97]  S. Katz,et al.  Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases , 2015, Clinical Cancer Research.

[98]  Eugene S. Kim,et al.  Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T-lymphocytes , 2015, Nature Medicine.

[99]  Lili Duan,et al.  Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer. , 2015, Cellular immunology.

[100]  Byeong-Cheol Ahn,et al.  In Vivo Cell Tracking with Bioluminescence Imaging , 2015, Nuclear Medicine and Molecular Imaging.

[101]  S. Millis,et al.  HER2 expression status in diverse cancers: review of results from 37,992 patients , 2015, Cancer and Metastasis Reviews.

[102]  E. Tartour,et al.  VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors , 2015, The Journal of experimental medicine.

[103]  Seth M Steinberg,et al.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.

[104]  J. Werner,et al.  Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells , 2015, Oncoimmunology.

[105]  Yujiang Fang,et al.  IL-35 promotes pancreas cancer growth through enhancement of proliferation and inhibition of apoptosis: evidence for a role as an autocrine growth factor. , 2014, Cytokine.

[106]  S. Bicciato,et al.  Human fibrocytic myeloid‐derived suppressor cells express IDO and promote tolerance via Treg‐cell expansion , 2014, European journal of immunology.

[107]  M. Brown,et al.  Mini Review Article , 2022 .

[108]  R. Jesenofsky,et al.  Desmoplasia and Chemoresistance in Pancreatic Cancer , 2014, Cancers.

[109]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[110]  Hao Liu,et al.  Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. , 2014, Cancer research.

[111]  S. Lutz,et al.  Redesigning Human 2′-Deoxycytidine Kinase Enantioselectivity for l-Nucleoside Analogues as Reporters in Positron Emission Tomography , 2014, ACS chemical biology.

[112]  Triantafyllos Stylianopoulos,et al.  The role of mechanical forces in tumor growth and therapy. , 2014, Annual review of biomedical engineering.

[113]  S. Grupp,et al.  Current concepts in the diagnosis and management of cytokine release syndrome. , 2014, Blood.

[114]  Stephen A. Sastra,et al.  Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. , 2014, Cancer cell.

[115]  Y. Ohshima,et al.  Marked elevation of interleukin-6 in mild encephalopathy with a reversible splenial lesion (MERS) associated with acute focal bacterial nephritis caused by Enterococcus faecalis , 2014, Brain and Development.

[116]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[117]  Will Liao,et al.  The cellular and molecular origin of tumor-associated macrophages , 2014, Science.

[118]  Xiao Zhao,et al.  Hypoxia-inducible factor-1 promotes pancreatic ductal adenocarcinoma invasion and metastasis by activating transcription of the actin-bundling protein fascin. , 2014, Cancer research.

[119]  Benjamin Rhau,et al.  Synthetic control of mammalian-cell motility by engineering chemotaxis to an orthogonal bioinert chemical signal , 2014, Proceedings of the National Academy of Sciences.

[120]  W. Burns,et al.  A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. , 2014, Human gene therapy.

[121]  D. Teachey,et al.  Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies , 2014, Cancer journal.

[122]  Qing He,et al.  Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.

[123]  Channing J Der,et al.  KRAS: feeding pancreatic cancer proliferation. , 2014, Trends in biochemical sciences.

[124]  R. Arnold,et al.  Investigating Conflict in ICUs—Is the Clinicians’ Perspective Enough?* , 2014, Critical care medicine.

[125]  D. Torigian,et al.  Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies , 2013, Cancer Immunology Research.

[126]  Michel Sadelain,et al.  PD-1– and CTLA-4–Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses , 2013, Science Translational Medicine.

[127]  Derek S. Chan,et al.  Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer , 2013, Proceedings of the National Academy of Sciences.

[128]  H. Abken,et al.  Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells , 2013, Front. Immunol..

[129]  N. Sato,et al.  Prognostic Impact of Hyaluronan and Its Regulators in Pancreatic Ductal Adenocarcinoma , 2013, PloS one.

[130]  J. Gribben,et al.  Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. , 2013, Gastroenterology.

[131]  S. Ghaem-Maghami,et al.  Preclinical In Vivo Modeling of Cytokine Release Syndrome Induced by ErbB-Retargeted Human T Cells: Identifying a Window of Therapeutic Opportunity? , 2013, The Journal of Immunology.

[132]  Paul H. Bessette,et al.  Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index , 2013, Science Translational Medicine.

[133]  Hao Liu,et al.  Interleukin-7 Mediates Selective Expansion of Tumor-redirected Cytotoxic T Lymphocytes (CTLs) without Enhancement of Regulatory T-cell Inhibition , 2013, Clinical Cancer Research.

[134]  P. Muranski,et al.  Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. , 2013, The Journal of clinical investigation.

[135]  P. Darcy,et al.  Blockade of PD-1 immunosuppression boosts CAR T-cell therapy , 2013, Oncoimmunology.

[136]  M. Magliano,et al.  Deciphering the role of stroma in pancreatic cancer , 2013, Current opinion in gastroenterology.

[137]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[138]  Hao Liu,et al.  Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[139]  C. Collins,et al.  Cancer-generated lactic acid: a regulatory, immunosuppressive metabolite? , 2013, The Journal of pathology.

[140]  Matthew L Baker,et al.  TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy , 2013, Molecular therapy. Nucleic acids.

[141]  P. Xie,et al.  M2-polarized tumor-associated macrophages promoted epithelial–mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway , 2013, Laboratory Investigation.

[142]  S. Rosenberg,et al.  Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia , 2013, The Journal of experimental medicine.

[143]  Qing He,et al.  CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia , 2013, Science Translational Medicine.

[144]  Xiao-li Zhang,et al.  Combining Hedgehog Signaling Inhibition with Focal Irradiation on Reduction of Pancreatic Cancer Metastasis , 2013, Molecular Cancer Therapeutics.

[145]  John M. Asara,et al.  Glutamine supports pancreatic cancer growth through a Kras-regulated metabolic pathway , 2013, Nature.

[146]  M A Firpo,et al.  The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. , 2013, Current molecular medicine.

[147]  R. Tomasini,et al.  Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma , 2013, Proceedings of the National Academy of Sciences.

[148]  Y. Kanai,et al.  Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer , 2013, British Journal of Cancer.

[149]  C. Wouters,et al.  Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. , 2012, The New England journal of medicine.

[150]  Michel Sadelain,et al.  Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells , 2012, Nature Biotechnology.

[151]  P. Altevogt,et al.  Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice. , 2012, Gastroenterology.

[152]  Navneeta Bansal,et al.  Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies , 2012, Clinical Cancer Research.

[153]  H. Abken,et al.  T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. , 2012, Gastroenterology.

[154]  Youping Deng,et al.  Effect of Pemetrexed on Innate Immune Killer Cells and Adaptive Immune T Cells in Subjects With Adenocarcinoma of the Pancreas , 2012, Journal of immunotherapy.

[155]  P. Romero,et al.  Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. , 2012, Cancer research.

[156]  D. Xie,et al.  TGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. , 2012, Cancer cell.

[157]  Triantafyllos Stylianopoulos,et al.  Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors , 2012, Proceedings of the National Academy of Sciences.

[158]  M. Mulcahy,et al.  A Multi-institutional Phase 2 Study of Imatinib Mesylate and Gemcitabine for First-Line Treatment of Advanced Pancreatic Cancer. , 2012, Gastrointestinal cancer research : GCR.

[159]  S. Eccles,et al.  Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling , 2012, Journal of Clinical Immunology.

[160]  H. Toyokawa,et al.  Circulating CD4+CD25+ Regulatory T Cells in Patients With Pancreatic Cancer , 2012, Pancreas.

[161]  Ahmedin Jemal,et al.  Cancers with increasing incidence trends in the United States: 1999 through 2008 , 2012, CA: a cancer journal for clinicians.

[162]  S. Russell,et al.  The Sodium Iodide Symporter (NIS) as an Imaging Reporter for Gene, Viral, and Cell-based Therapies , 2012, Current gene therapy.

[163]  K. Schlie,et al.  When Cells Suffocate: Autophagy in Cancer and Immune Cells under Low Oxygen , 2011, International journal of cell biology.

[164]  Michel Sadelain,et al.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. , 2011, Blood.

[165]  Claudiu T. Supuran,et al.  Interfering with pH regulation in tumours as a therapeutic strategy , 2011, Nature Reviews Drug Discovery.

[166]  R. Hruban,et al.  Pancreatic cancer , 2011, The Lancet.

[167]  David L. Porter,et al.  T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.

[168]  H. Abken,et al.  IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. , 2011, Cancer research.

[169]  G. Haegeman,et al.  Interleukin-6, a mental cytokine , 2011, Brain Research Reviews.

[170]  L. Coussens,et al.  B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis , 2011, Proceedings of the National Academy of Sciences.

[171]  D. Stocken,et al.  Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13 , 2011, Cancer Immunology, Immunotherapy.

[172]  Jing Sun,et al.  Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor , 2011, Clinical Cancer Research.

[173]  S. Natsugoe,et al.  Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. , 2011, The Journal of surgical research.

[174]  Hao Liu,et al.  CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. , 2011, The Journal of clinical investigation.

[175]  Byeong-Cheol Ahn,et al.  Applications of molecular imaging in drug discovery and development process. , 2011, Current pharmaceutical biotechnology.

[176]  A. McKinney,et al.  Toxic leukoencephalopathy following fludarabine-associated hematopoietic cell transplantation. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[177]  C. Rudin,et al.  Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors , 2011, Clinical Cancer Research.

[178]  P. O'Connor,et al.  Enzymatic Depletion of Tumor Hyaluronan Induces Antitumor Responses in Preclinical Animal Models , 2010, Molecular Cancer Therapeutics.

[179]  J. Spicer,et al.  Selective Expansion of Chimeric Antigen Receptor-targeted T-cells with Potent Effector Function using Interleukin-4* , 2010, The Journal of Biological Chemistry.

[180]  Robert E. Hawkins,et al.  The Optimal Antigen Response of Chimeric Antigen Receptors Harboring the CD3ζ Transmembrane Domain Is Dependent upon Incorporation of the Receptor into the Endogenous TCR/CD3 Complex , 2010, The Journal of Immunology.

[181]  N. Jayaprakash,et al.  The serum and cerebrospinal fluid pharmacokinetics of anakinra after intravenous administration to non-human primates , 2010, Journal of Neuroimmunology.

[182]  H. Heslop,et al.  Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety , 2010, Leukemia.

[183]  M. Sadelain,et al.  Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[184]  S. Rosenberg,et al.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[185]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[186]  L. Yang,et al.  Activation of the hedgehog-signaling pathway in human cancer and the clinical implications , 2010, Oncogene.

[187]  E. Repasky,et al.  Hypoxia-driven immunosuppression: A new reason to use thermal therapy in the treatment of cancer? , 2010, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[188]  Yaojiong Wu,et al.  CD133 as a marker for cancer stem cells: progresses and concerns. , 2009, Stem cells and development.

[189]  P. V. van Diest,et al.  HER-family gene amplification and expression in resected pancreatic cancer. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[190]  R. Jaster,et al.  Molecular determinants of the profibrogenic effects of endothelin-1 in pancreatic stellate cells. , 2009, World journal of gastroenterology.

[191]  G. Scambia,et al.  Targeting CD133 antigen in cancer , 2009, Expert opinion on therapeutic targets.

[192]  M. B. Gillespie,et al.  Secretion of vascular endothelial growth factor by oral squamous cell carcinoma cells skews endothelial cells to suppress T-cell functions. , 2009, Human immunology.

[193]  T. Giese,et al.  Regulation of NK Cell Function by Human Granulocyte Arginase1 , 2009, The Journal of Immunology.

[194]  C. Yee,et al.  Fludarabine Modulates Immune Response and Extends In Vivo Survival of Adoptively Transferred CD8 T Cells in Patients with Metastatic Melanoma , 2009, PloS one.

[195]  R. Pazdur,et al.  Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. , 2009, The oncologist.

[196]  Richard P. Junghans,et al.  Second-Generation Anti–Carcinoembryonic Antigen Designer T Cells Resist Activation-Induced Cell Death, Proliferate on Tumor Contact, Secrete Cytokines, and Exhibit Superior Antitumor Activity In vivo: A Preclinical Evaluation , 2008, Clinical Cancer Research.

[197]  H. Friess,et al.  Pancreatic Islet and Stellate Cells Are the Main Sources of Endocrine Gland-Derived Vascular Endothelial Growth Factor/Prokineticin-1 in Pancreatic Cancer , 2008, Pancreatology.

[198]  Helmut Friess,et al.  The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[199]  H. Heslop,et al.  Antitumor Activity of EBV-specific T Lymphocytes Transduced With a Dominant Negative TGF-β Receptor , 2008, Journal of immunotherapy.

[200]  S. Rosenberg,et al.  Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. , 2008, Human gene therapy.

[201]  David Goldstein,et al.  Pancreatic stellate cells: partners in crime with pancreatic cancer cells. , 2008, Cancer research.

[202]  S. Natsugoe,et al.  CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer , 2008, British Journal of Cancer.

[203]  F. Farzaneh,et al.  Harnessing the tumour-derived cytokine, CSF-1, to co-stimulate T-cell growth and activation. , 2008, Molecular immunology.

[204]  A. Molven,et al.  Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas , 2008, BMC Cancer.

[205]  K. Foon,et al.  Carcinoembryonic Antigen Transgenic Mouse Models for Immunotherapy and Development of Cancer Vaccines , 2008, Current protocols in immunology.

[206]  Michel Sadelain,et al.  In vivo imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene. , 2007, Cancer research.

[207]  Y. Wang,et al.  Involvement of cellular death in TRAIL/DR5-dependent suppression induced by CD4+CD25+ regulatory T cells , 2007, Cell Death and Differentiation.

[208]  S. Ishihara,et al.  CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation–mediated apoptosis of effector CD4+ T cells , 2007, Nature Immunology.

[209]  R. Weissleder,et al.  In vivo imaging of T cell delivery to tumors after adoptive transfer therapy , 2007, Proceedings of the National Academy of Sciences.

[210]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[211]  Gregor Rothe,et al.  Inhibitory effect of tumor cell-derived lactic acid on human T cells. , 2007, Blood.

[212]  D. V. Von Hoff,et al.  Tumor-stroma interactions in pancreatic ductal adenocarcinoma , 2007, Molecular Cancer Therapeutics.

[213]  R. Lechler,et al.  Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. , 2007, Blood.

[214]  A. Scarpa,et al.  Cooperative Induction of a Tolerogenic Dendritic Cell Phenotype by Cytokines Secreted by Pancreatic Carcinoma Cells1 , 2006, The Journal of Immunology.

[215]  Yongliang Zhang,et al.  Regulation of T cell activation and tolerance by PDL2. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[216]  U. Grohmann,et al.  The Combined Effects of Tryptophan Starvation and Tryptophan Catabolites Down-Regulate T Cell Receptor ζ-Chain and Induce a Regulatory Phenotype in Naive T Cells1 , 2006, The Journal of Immunology.

[217]  Daniel T. Fisher,et al.  Hurdles to Lymphocyte Trafficking in the Tumor Microenvironment: Implications for Effective Immunotherapy , 2006, Immunological investigations.

[218]  M. Lerner,et al.  Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. , 2005, American journal of clinical pathology.

[219]  J. Greiner,et al.  Mouse models expressing human carcinoembryonic antigen (CEA) as a transgene: evaluation of CEA-based cancer vaccines. , 2005, Mutation research.

[220]  David C. Gondek,et al.  Cutting Edge: Contact-Mediated Suppression by CD4+CD25+ Regulatory Cells Involves a Granzyme B-Dependent, Perforin-Independent Mechanism1 , 2005, The Journal of Immunology.

[221]  M. Büchler,et al.  Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[222]  Frieder Keller,et al.  Pharmacokinetics and Pharmacodynamics of Systemically Administered Glucocorticoids , 2005, Clinical Pharmacokinetics.

[223]  F. Mullick,et al.  Presence and Localization of Three Lactic Acid Transporters (MCT1, −2, and −4) in Separated Human Granulocytes, Lymphocytes, and Monocytes , 2004, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[224]  J S Wilson,et al.  Desmoplastic Reaction in Pancreatic Cancer: Role of Pancreatic Stellate Cells , 2004, Pancreas.

[225]  H. Kitagawa,et al.  Fas ligand expression in human pancreatic cancer. , 2004, Oncology reports.

[226]  R. Hruban,et al.  Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer Patients , 2004, The Journal of experimental medicine.

[227]  Rakesh K. Jain,et al.  Pathology: Cancer cells compress intratumour vessels , 2004, Nature.

[228]  T. Oshikiri,et al.  CD8+ Tumor-Infiltrating Lymphocytes Together with CD4+ Tumor-Infiltrating Lymphocytes and Dendritic Cells Improve the Prognosis of Patients with Pancreatic Adenocarcinoma , 2004, Pancreas.

[229]  Y. Nakajima,et al.  Prognostic significance of HIF-1 alpha overexpression in human pancreatic cancer. , 2003, Anticancer research.

[230]  Gregory Y. Lauwers,et al.  Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis , 2003, Nature.

[231]  J S Wilson,et al.  Cell migration: a novel aspect of pancreatic stellate cell biology , 2003, Gut.

[232]  P. Allavena,et al.  Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. , 2002, Trends in immunology.

[233]  H. Petty,et al.  Molecular proximity of seprase and the urokinase-type plasminogen activator receptor on malignant melanoma cell membranes: dependence on beta1 integrins and the cytoskeleton. , 2002, Carcinogenesis.

[234]  J. Ochoa,et al.  Regulation of T Cell Receptor CD3ζ Chain Expression byl-Arginine* , 2002, The Journal of Biological Chemistry.

[235]  C. Thompson,et al.  The CD28 signaling pathway regulates glucose metabolism. , 2002, Immunity.

[236]  M. Lotze,et al.  Paucity of dendritic cells in pancreatic cancer. , 2002, Surgery.

[237]  J. Cameron,et al.  Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[238]  M Locati,et al.  Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. , 2001, Trends in immunology.

[239]  A. Lardner.  The effects of extracellular pH on immune function , 2001, Journal of leukocyte biology.

[240]  H. Kalthoff,et al.  Systemic and local immunosuppression in pancreatic cancer patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[241]  K. Lillemoe,et al.  Resected adenocarcinoma of the pancreas— 616 patients: Results, outcomes, and prognostic indicators , 2000, Journal of Gastrointestinal Surgery.

[242]  D. Munn,et al.  Inhibition of  T Cell Proliferation by Macrophage Tryptophan Catabolism , 1999, The Journal of experimental medicine.

[243]  S. Hammarström.  The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. , 1999, Seminars in cancer biology.

[244]  M. Korsten,et al.  Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture , 1998, Gut.

[245]  C. Bordignon,et al.  HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. , 1997, Science.

[246]  T. Saito,et al.  Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[247]  T. Reynolds,et al.  T–cell mediated rejection of gene–modified HIV–specific cytotoxic T lymphocytes in HIV–infected patients , 1996, Nature Medicine.

[248]  I. Pastan,et al.  Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[249]  W. Banks,et al.  Blood-borne interleukin-1 receptor antagonist crosses the blood-brain barrier , 1994, Journal of Neuroimmunology.

[250]  B. Cheson,et al.  Neurotoxicity of purine analogs: a review. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[251]  H. Friess,et al.  Overexpression of HER2/neu oncogene in human pancreatic carcinoma. , 1993, Human pathology.

[252]  Z. Eshhar,et al.  Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[253]  I. Pastan,et al.  Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium , 1992, International journal of cancer.

[254]  Arthur Weiss,et al.  The cytoplasmic domain of the T cell receptor ζ chain is sufficient to couple to receptor-associated signal transduction pathways , 1991, Cell.

[255]  P. Hwu,et al.  Chimeric antigen receptor T-cell therapy — assessment and management of toxicities , 2018, Nature Reviews Clinical Oncology.

[256]  N. Bhattacharya,et al.  An Immunosuppressive Dendritic Cell Subset Accumulates at Secondary Sites and Promotes Metastasis in Pancreatic Cancer. , 2017, Cancer research.

[257]  C. June,et al.  Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms , 2017, Leukemia.

[258]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[259]  E. Eichler,et al.  Evolutionary-new centromeres preferentially emerge within gene deserts , 2008, Genome Biology.

[260]  K. Hirakawa,et al.  Role of tumor-infiltrating CD11b+ antigen-presenting cells in the progression of gastric cancer. , 2014, The Journal of surgical research.

[261]  Carolina Gutierrez,et al.  HER2: biology, detection, and clinical implications. , 2011, Archives of pathology & laboratory medicine.

[262]  Christian M. Metallo,et al.  Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth , 2013 .

[263]  R. Schiff,et al.  HER 2: Biology, Detection, and Clinical Implications , 2011 .

[264]  C. Marshall,et al.  Regulation of cell signalling by uPAR , 2010, Nature Reviews Molecular Cell Biology.

[265]  H. Heslop.  Safer CARS. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[266]  A. Adjei,et al.  Protection against fludarabine neurotoxicity in leukemic mice by the nucleoside transport inhibitor nitrobenzylthioinosine , 2004, Cancer Chemotherapy and Pharmacology.

[267]  Michel Sadelain,et al.  Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor , 2002, Nature Biotechnology.